AbbVie (ABBV): Dividend Yield, Returns & Analysis

AbbVie (NYSE: ABBV) is one of the highest-yielding Dividend Aristocrats in the pharmaceutical sector, offering investors a combination of above-average income and a track record of consistent dividend growth. Spun off from Abbott Laboratories in 2013, AbbVie inherited the blockbuster drug Humira — for years the world’s best-selling pharmaceutical — along with Abbott’s long dividend history, which means it counts those pre-spinoff years toward its Aristocrat status.

The central challenge AbbVie has faced in recent years is the loss of Humira’s US exclusivity in early 2023, which opened the door to biosimilar competition. Despite legitimate concerns at the time, the company has navigated this transition more effectively than many analysts expected, with newer immunology drugs Skyrizi and Rinvoq ramping up strongly to offset declining Humira revenues. The acquisition of Allergan in 2020 — bringing in Botox and a broader aesthetics portfolio — further diversified the revenue base away from a single dependency.

For dividend investors, AbbVie is notable for its generous yield, which typically ranges between 3.5% and 5% depending on where the share price is trading. The payout has been increased every year since the spinoff, and management has consistently signalled commitment to maintaining that growth. While pharmaceutical stocks carry pipeline and regulatory risk, AbbVie’s broad drug portfolio, strong free cash flow generation, and dividend track record make it a compelling high-yield option for income-focused portfolios.